The role of VEGF-directed drugs in the treatment of diabetic retinopathy and macular edema: What an endocrinologist needs to know

Diabetic retinopathy (DR) and diabetic macular edema (DME) are the most common microangiopathic complications of diabetes mellitus, that represent one of the most relevant problems of modern healthcare. DR is the fifth most common cause of blindness worldwide and the main cause of vision loss in patients with diabetes. Proliferative DR (PDR) is the last stage of this complex retinal disease and is characterized by abnormal production of vascular endothelial growth factor (VEGF), which is one of the most important pathogenic factors of DR. based on the current data on DR development and the role of VEGF, there can be identified several therapeutic strategies. Panretinal photocoagulation (PRP) is the standard treatment for proliferative diabetic retinopathy. In addition, combination of PRP and intravitreal administration of antiVEGF drugs is considered the most effective method for the management of DME. Modern strategies in diabetology and ophthalmology include anti-VEGF therapy that has radically changed the outcome of DR due to its antiangiogenic activity. Currently, the most effective anti-VEGF drugs are ranibizumab, brolucizumab and aflibercept. They have significantly changed the prognosis of patients, due to achieving better visual acuity and preventing the progression of DR and vision-threatening complications. In the present review, we have provided up-to-date information on the role of VEGF in the pathogenesis of DR, as well as on the current management strategies of DR and DMO. 

1. GBD 2019 Blindness and Visual Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and visual impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to vision 2020: The Right to Sight: An analysis for the Global Burden of Disease Study. Lancet Glob Health 2021;9(2):e144–60. doi: 10.1016/S2214-109X(20)30489-7.

2. Клинические рекомендации: Сахарный диабет: ретинопатия диабетическая, макулярный отёк диабетический / Министерство Здравоохранения Российской Федерации. — 2023. — URL: https://cr.minzdrav.gov.ru/viewcr/115_2 (дата обращения: [12.02.2025]).

3. Дедов И.И., Шестакова М.В., Майоров А.Ю., Мокрышева Н.Г., Андреева Е.Н., Безлепкина О.Б. с соавт. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й выпуск. Сахарный диабет. 2023;26(S2):1– 157. doi: 10.14341/DM13042.

4. Wu MY, Yiang GT, Lai TT, Li CJ. The oxidative stress and mitochondrial dysfunction during the pathogenesis of diabetic retinopathy. Oxid Med Cell Longev. 2018;2018:3420187. doi: 10.1155/2018/3420187.

5. Yang J, Liu Z. Mechanistic pathogenesis of endothelial dysfunction in diabetic nephropathy and retinopathy. Front Endocrinol (Lausanne). 2022;13:816400. doi: 10.3389/fendo.2022.816400.

6. Mesquita J, Castro-de-Sousa JP, Vaz-Pereira S, Neves A, Passarinha LA, Tomaz CT. Vascular endothelial growth factors and placenta growth factor in retinal vasculopathies: Current research and future perspectives. Cytokine Growth Factor Rev. 2018;39:102–15. doi: 10.1016/j.cytogfr.2017.11.005.

7. Diabetes Control and Complications Trial Research Group; Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86. doi: 10.1056/NEJM199309303291401.

8. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia. 1991;34(12):877–90.

9. Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev. 2015;1:CD006127. doi: 10.1002/14651858.CD006127.pub2. Update in: Cochrane Database Syst Rev. 2023;3(3):CD006127. doi: 10.1002/14651858.CD006127.pub3.

10. Rao H, Jalali JA, Johnston TP, Koulen P. Emerging roles of dyslipidemia and hyperglycemia in diabetic retinopathy: Molecular mechanisms and clinical perspectives. Front Endocrinol (Lausanne). 2021;12:620045. doi: 10.3389/fendo.2021.620045.

11. ACCORD Study Group; ACCORD Eye Study Group; Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233–44. doi: 10.1056/NEJMoa1001288.

12. Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol. 1996;114(9):1079–84. doi: 10.1001/archopht.1996.01100140281004.

13. Liu L, Yue S, Wu J, Zhang J, Lian J, Teng W et al. Prevalence and risk factors of retinopathy in patients with or without metabolic syndrome: A population-based study in Shenyang. BMJ Open. 2015;5(12):e008855. doi: 10.1136/bmjopen-2015-008855.

14. Spaide RF, Klancnik JM Jr, Cooney MJ. Retinal vascular layers imaged by fluorescein angiography and optical coherence tomography angiography. JAMA Ophthalmol. 2015;133(1):45–50. doi: 10.1001/jamaophthalmol.2014.3616.

15. Wang B, Wang F, Zhang Y, Zhao SH, Zhao WJ, Yan SL, Wang YG. Effects of RAS inhibitors on diabetic retinopathy: A systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3(4):263–74. doi: 10.1016/S2213-8587(14)70256-6.

16. Patel A; ADVANCE Collaborative Group; MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet. 2007;370(9590):829–40. doi: 10.1016/S0140-6736(07)61303-8.

17. Kataoka SY, Lois N, Kawano S, Kataoka Y, Inoue K, Watanabe N. Fenofibrate for diabetic retinopathy. Cochrane Database Syst Rev. 2023;6(6):CD013318. doi: 10.1002/14651858.CD013318.pub2.

18. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185–222. doi: 10.1159/000458539.

19. Wong TY, Sun J, Kawasaki R, Ruamviboonsuk P, Gupta N, Lansingh VC et al. Guidelines on diabetic eye care: The International Council of Ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology. 2018;125(10):1608–22. doi: 10.1016/j.ophtha.2018.04.007.

20. Solomon SD, Chew E, Duh EJ, Sobrin L, Sun JK, VanderBeek BL et al. Diabetic retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40(3):412–18. doi: 10.2337/dc16-2641.

21. Lin KY, Hsih WH, Lin YB, Wen CY, Chang TJ. Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy. J Diabetes Investig. 2021;12(8):1322–25. doi: 10.1111/jdi.13480.

22. Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV et al; READ-2 Study Group. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117(11):2146–51. doi: 10.1016/j.ophtha.2010.08.016.

23. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33(11):2399–405. doi: 10.2337/dc10-0493.

24. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO et al.; RESTORE study group. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615–25. doi: 10.1016/j.ophtha.2011.01.031.

25. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L et al.; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801. doi: 10.1016/j.ophtha.2011.12.039.

26. Brown DM, Schmidt-Erfurth U, Do DV, Holz FG, Boyer DS, Midena E et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 2015;122(10):2044–52. doi: 10.1016/j.ophtha.2015.06.017.

27. Wykoff CC, Le RT, Khurana RN, Brown DM, Ou WC, Wang R et al.; ENDURANCE Study Group. Outcomes with as-needed aflibercept and macular laser following the phase III VISTA DME Trial: ENDURANCE 12-month extension study. Am J Ophthalmol. 2017;173:56–63. doi: 10.1016/j.ajo.2016.09.029.

28. Brown DM, Emanuelli A, Bandello F, Barranco JJE, Figueira J, Souied E et al. KESTREL and KITE: 52-week results from two phase iii pivotal trials of brolucizumab for diabetic macular edema. Am J Ophthalmol. 2022;238:157–72. doi: 10.1016/j.ajo.2022.01.004.

29. Arrigo A, Aragona E, Bandello F. VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy. Ann Med. 2022;54(1):1089– 111. doi:10.1080/07853890.2022.2064541.

30. Rittiphairoj T, Mir TA, Li T, Virgili G. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev. 2020;11(11):CD005656. doi: 10.1002/14651858.CD005656.pub3.

31. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1987;94(7):761–74. doi: 10.1016/s0161-6420(87)33527-4.

32. Sivaprasad S, Prevost AT, Vasconcelos JC, Riddell A, Murphy C, Kelly J et al.; CLARITY Study Group. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): A multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet. 2017;389(10085):2193–203. doi: 10.1016/S0140-6736(17)31193-5.

33. Gross JG, Glassman AR, Liu D, Sun JK, Antoszyk AN, Baker CW et al.; Diabetic Retinopathy Clinical Research Network. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA Ophthalmol. 2018;136(10):1138–48. doi: 10.1001/jamaophthalmol.2018.3255.

34. Comyn O, Sivaprasad S, Peto T, Neveu MM, Holder GE, Xing W et al. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). Am J Ophthalmol. 2014;157(5):960– 70. doi: 10.1016/j.ajo.2014.02.019.